Senior Disease Expert - Oncology

The following content displays a map of the jobs location - Remote

Location: UK or US preferred; hybrid or remote working considered

Pharmaron is a global contract research and manufacturing organization (CRO/CDMO)helping pharma and biotech companies bring new therapies to life. With over 25,000 employees worldwide across 28 locations in the UK, US, China, and Singapore, we support drug discovery through to manufacturing with fully integrated high-quality services.

We're proud of the impact we make and just last year, we supported 887 discovery projects, 1,100+ CMC programs, and 1,397 clinical trialsacross all phases. Our teams are involved in everything from small molecules, ADC's, biologics, and gene therapies and we work with more than 3,300 global customers. To learn more, visit

Pharmaron is looking to appoint a Senior Oncology Specialist to provide disease-area leadership across our Integrated Drug Discovery activities. The role will help project teams and clients convert oncology insight into practical discovery plans, with particular emphasis on biological rationale, model selection, translational endpoints and evidence packages that support clear programme decisions.

This position would suit an experienced oncology scientist or clinician-scientist who can combine deep disease knowledge with a pragmatic understanding of drug discovery. The successful candidate will work across Pharmaron's global scientific network and with external partners to strengthen programme design, interpret complex datasets and identify opportunities to improve how oncology projects are progressed from early concept towards candidate selection and IND preparation.

• Act as the senior oncology voice within discovery programmes and across Pharmaron, enabling teams to define the disease context, therapeutic rationale and experiments needed to test key hypotheses.
• Shape project strategies so that early biology, pharmacology and translational plans are connected from the outset and remain aligned with the intended clinical opportunity.
• Advise on selection and use of oncology models, assay systems, pharmacodynamic readouts, biomarker development and translational endpoints that are appropriate for